Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation

Fig. 7

Naringenin (Nar) inhibits the activation of PKC-ε and PKC-ζ. a Analysis of the relative mRNA level of PRKCE, PRKCZ, and Tgf-β1 in 4T1 cells treated with 100 μM of Nar for 24 hours with or without transfection using the siRNAs of PRKCE or PRKCZ. b Western blot analysis of PKC-ε, p-PKC-ε, PKC-ζ, and p-PKC-ζ expression in 4T1 cells treated with Nar for 48 hours with or without transfection using siRNAs of PRKCE or PRKCZ. Imaging of western blot bands (left) and quantitative data of protein expression relative to GAPDH from three repeats (right). c Cellular and secreted TGF-β1 concentrations of 4T1 cells treated with Nar for 48 hours with or without transfection using the siRNAs of PRKCE or PRKCZ. d Confocal imaging of TGF-β1 and TGN in 4T1 cells treated with Nar, phorbol 12-myristate 13-acetate (PMA), calphostin C (Cal), the combination of Nar and PMA, or Nar and Cal for 48 hours. e, f Cellular e and secreted f TGF-β1 concentrations of 4T1 cells treated with Nar, PMA, Cal, the combination of Nar and PMA, or Nar and Cal for 48 hours. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. GAPDH glyceraldehyde 3-phosphate dehydrogenase, PKC protein kinase C, TGF transforming growth factor, PMA phorbol 12-myristate 13-acetate

Back to article page